Hudson Bay Capital Management
MDGL icon

Hudson Bay Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Hudson Bay Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,000
Closed -$2.29M – 1402
2025
Q3 		$2.29M Buy
+5,000
New +$1.87M 0.01% 729

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hudson Bay Capital Management's MDGL Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 2,000 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #906 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in MDGL as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in MDGL in Q4 2017 and has held it in 5 quarters since. The position peaked at $5.26M in Q1 2018. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Hudson Bay Capital Management held 2,000 shares of Madrigal Pharmaceuticals worth $1.07M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Hudson Bay Capital Management position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #906 holding.
  • Hudson Bay Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 5 quarters since.
  • Hudson Bay Capital Management's Madrigal Pharmaceuticals position peaked at $5.26M in Q1 2018.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.